Literature DB >> 12706940

Obesity is associated with increased levels of circulating hepatocyte growth factor.

Jalees Rehman1, Robert V Considine, Jason E Bovenkerk, Jingling Li, Catharine A Slavens, Rose Marie Jones, Keith L March.   

Abstract

OBJECTIVES: This study evaluated whether obesity in humans was associated with an increase in circulating hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) levels.
BACKGROUND: Obesity acts as a cardiovascular risk factor by mechanisms that are not fully understood. Adipose tissue is able to secrete multiple cytokines and growth factors ex vivo. We hypothesized that the increased presence of adipose tissue in obese subjects results in systemic elevations of the mitogenic factors HGF and VEGF.
METHODS: Blood samples were obtained from lean (n = 21) and obese (n = 44) volunteers. Serum HGF and VEGF levels were assessed by enzyme-linked immunoadsorbent assay. Insulin and fasting glucose levels were measured to evaluate insulin sensitivity. Conditioned medium of adipose cells was assayed for HGF secretion.
RESULTS: Serum HGF levels in obese subjects were more than three-fold higher than those of lean subjects (2,462 +/- 184 pg/ml vs. 765 +/- 48 pg/ml, p < 0.0001). The VEGF levels were not significantly elevated in obese subjects (135 +/- 31 pg/ml vs. 128 +/- 37 pg/ml). The HGF concentrations, but not VEGF concentrations, were significantly correlated with body mass index (BMI) (p < 0.0001, r = 0.74). The observed increases in HGF concentrations of obese subjects were not secondary to insulin resistance or hypertension. Freshly isolated human adipose cells secreted HGF.
CONCLUSIONS: Our results indicate that obesity is associated with a marked increase in circulating HGF levels, which correlate linearly with BMI. Because vascular growth factors have been associated with the pathogenesis of atherosclerosis, the possible role of such humoral factors as a link between obesity and cardiovascular disease is very intriguing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706940     DOI: 10.1016/s0735-1097(03)00231-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  44 in total

1.  Novel proapoptotic effect of hepatocyte growth factor: synergy with palmitate to cause pancreatic {beta}-cell apoptosis.

Authors:  José A González-Pertusa; John Dubé; Shelley R Valle; Taylor C Rosa; Karen K Takane; José M Mellado-Gil; Germán Perdomo; Rupangi C Vasavada; Adolfo García-Ocaña
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

2.  Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study.

Authors:  Rihong Zhai; Yang Zhao; Geoffrey Liu; Monica Ter-Minassian; I-Chen Wu; Zhaoxi Wang; Li Su; Kofi Asomaning; Feng Chen; Matthew H Kulke; Xihong Lin; Rebecca S Heist; John C Wain; David C Christiani
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

3.  Trans-ethnic meta-analysis identifies common and rare variants associated with hepatocyte growth factor levels in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Nicholas B Larson; Cecilia Berardi; Paul A Decker; Christina L Wassel; Phillip S Kirsch; James S Pankow; Michele M Sale; Mariza de Andrade; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Michael Y Tsai; Kent D Taylor; Suzette J Bielinski
Journal:  Ann Hum Genet       Date:  2015-05-22       Impact factor: 1.670

4.  Increased plasma levels of soluble vascular endothelial growth factor receptor 1 (sFlt-1) in women by moderate exercise and increased plasma levels of vascular endothelial growth factor in overweight/obese women.

Authors:  Kristina L Makey; Sharla G Patterson; James Robinson; Mark Loftin; Dwight E Waddell; Lucio Miele; Edmund Chinchar; Min Huang; Andrew D Smith; Mark Weber; Jian-Wei Gu
Journal:  Eur J Cancer Prev       Date:  2013-01       Impact factor: 2.497

5.  Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia.

Authors:  Radosław Wieczór; Anna Maria Wieczór; Grażyna Gadomska; Katarzyna Stankowska; Jacek Fabisiak; Karol Suppan; Grzegorz Pulkowski; Jacek Budzyński; Danuta Rość
Journal:  J Zhejiang Univ Sci B       Date:  2016 Nov.       Impact factor: 3.066

6.  Reproducibility of serum cytokines and growth factors.

Authors:  Yian Gu; Anne Zeleniuch-Jacquotte; Faina Linkov; Karen L Koenig; Mengling Liu; Lyudmila Velikokhatnaya; Roy E Shore; Adele Marrangoni; Paolo Toniolo; Anna E Lokshin; Alan A Arslan
Journal:  Cytokine       Date:  2008-12-05       Impact factor: 3.861

Review 7.  Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review.

Authors:  John N Fain
Journal:  Mediators Inflamm       Date:  2010-05-23       Impact factor: 4.711

8.  Hepatocyte growth factor and clinical diabetes in postmenopausal women.

Authors:  Swapnil N Rajpathak; Sylvia Wassertheil-Smoller; Jill Crandall; Simin Liu; Gloria Y F Ho
Journal:  Diabetes Care       Date:  2010-06-02       Impact factor: 19.112

9.  White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models.

Authors:  Yan Zhang; Alexes Daquinag; Dmitry O Traktuev; Felipe Amaya-Manzanares; Paul J Simmons; Keith L March; Renata Pasqualini; Wadih Arap; Mikhail G Kolonin
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

10.  Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells.

Authors:  German Perdomo; Maria A Martinez-Brocca; Bankim A Bhatt; Nicholas F Brown; Robert M O'Doherty; Adolfo Garcia-Ocaña
Journal:  J Biol Chem       Date:  2008-03-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.